Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
Quick Look: Asahi Kasei is expanding its pharma footprint through a €780 million deal for Germany’s Aicuris, advancing its drive toward 300 billion yen in sales by FY2030. The transaction adds royalty income from Prevymis and antiviral pipeline assets, reinforcing…
To read the full story
Related Article
- Asahi Kasei Closes Aicuris Buy, Eyes US$500 Million Sales by 2030
April 21, 2026
- Asahi Kasei Confident of Hitting 2027 Profit Goal, Tarpeyo as Pharma Growth Driver
April 16, 2026
- Asahi Kasei Banks on Tarpeyo to Hit 300 Billion Yen in Pharma Sales by FY2030
March 26, 2026
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
- Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
December 10, 2025
- Asahi Kasei Sharpens Acquisition Focus in Pharma Biz as Envarsus LOE Looms
July 15, 2025
- Asahi Kasei on Hunt for M&A and Licensing Deals to Bolster Pharma Biz
April 15, 2025
- Asahi Kasei to Divest Diagnostics Biz to Nagase in July 2025
September 27, 2024
- Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
- Asahi Kasei to Divest Medical Devices Unit to Integral, but Retains Bioprocess Biz
September 19, 2024
BUSINESS
- Keytruda Holds Top Spot for 35th Straight Month in August: Encise
September 7, 2026
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…